Summit Therapeutics (NASDAQ:SMMT) Receives Market Outperform Rating from JMP Securities
JMP Securities reaffirmed their market outperform rating on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a report published on Monday morning,Benzinga reports. They currently have a $40.00 price target on the stock. SMMT has been the topic of a number of other reports. Cantor Fitzgerald restated an “overweight” rating on shares of Summit […]
JMP Securities reaffirmed their market outperform rating on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a report published on Monday morning,Benzinga reports. They currently have a $40.00 price target on the stock. SMMT has been the topic of a number of other reports. Cantor Fitzgerald restated an “overweight” rating on shares of Summit […]
